50results about How to "Reduced potency" patented technology

A serious of nitro heterocyclic derivatives including a structure of formula (I) are provided. In formula (I), P, Q and R1 to R8 are defined in the specification. The derivatives disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

The present invention relates to an antibody comprising a GlcNAc-S(A)x substituent, wherein S(A)x is a sugar derivative comprising x functional groups A wherein A is independently selected from the group consisting of an azido group, a keto group and an alkynyl group and x is 1, 2, 3 or 4, wherein said GlcNAc-S(A)x substituent is bonded to the antibody via CI of the N-acetylglucosamine of said GlcNAc-S(A)x substituent, and wherein said N-acetylglucosamine is optionally fucosylated. The invention also relates to an antibody-conjugate, in particular to an antibody-conjugate according to the Formula (20) or (20b), wherein AB is an antibody, S is a sugar or a sugar derivative, D is a molecule of interest, and wherein said N-acetylglucosamine is optionally fucosylated (b is 0 or 1). The invention further relates to a process for the preparation of a modified antibody, to a process for the preparation of an antibody-conjugate, and to said antibody-conjugate for use as a medicament. In addition, the invention relates to a kit of parts comprising an azide-modified antibody and a linker-conjugate, wherein said linker-conjugate comprises a (hetero)cycloalkynyl group and one or more molecules of interest.

Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject.

The present invention is a composition identified as a region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of the ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells. Medicines may be in the form of antibodies, si-RNA and small molecules that recognize the region.

The invention relates to a novel poultry micro-ecological preparation and a preparation method of the novel poultry micro-ecological preparation. The preparation comprises following components in part by weight: 0.8-3.5 parts of vitamin A, 0.2-0.8 part of vitamin D, 2-8 parts of vitamin E, 0.2-1.2 parts of vitamin K, 0.1-0.9 part of vitamin B1, 0.2-0.8 part of vitamin B2, 0.1-0.7 part of vitamin B6, 0.08-0.5 part of vitamin B12, 2-5 parts of nicotinamide, 0.8-3.5 parts of calcium pantothenate, 0.02-0.4 part of folic acid, 0.2-1.2 parts of biotin, 0.02-2 parts of vitamin C, 1.3-32 parts of enterococcus faecium, 27-155 parts of bacillus subtilis, 75-210 parts of oligosaccharide, 150-400 parts of pine needle meal and 400-600 parts of bentonite. The novel poultry micro-ecological preparation can improve daily gain, feed intake, feed conversation efficiency of young poultry, reduces death and culling rate of the young poultry, and improves reproductive performance of breeding poultry, laying rate, fertilization rate of hatching eggs, hatching rate, and healthy rate of the young poultry. According to the invention, as double-layer shallow coating is performed to enterococcus faecium, the stress resistance of enterococcus faecium is improved.

Disclosed are a liquid product of botulinum toxin type A and a method for conserving the potency of botulinum toxin type A using a dextrose solution. Free of a stabilizer, such as albumin or gelatin, the liquid product of botulinum toxin type A completely excludes the possibility of cross infections such as AIDS and bovine spongiform encephalopathy. In addition, botulinum toxin type A is preserved as a liquid product in combination with a dextrose solution and can be clinically used as is, without the aid of physiological saline. Therefore, the liquid product enjoys the advantage of being convenient for use and avoiding a decrease in the potency as occurs upon dilution with physiological saline. Serving as a natural preserving and stabilizing agent, the dextrose solution allows botulinum toxin type A to be stored and distributed in the form of liquid phase over a long period of time and conserves the potency of the toxin at a constant level, which in turn guarantees constant clinical results.

A method of ameliorating the hidden node problem in wireless local area networks employing power control is disclosed. The illustrative embodiments function in a variety of ways that have a common theme: while the Data Frames are transmitted at lesser potency, at least one of the control frames—Request-to-Send, Clear-to-Send, and Acknowledgement—associated with the Data Frame are sent at a greater potency. This causes at least one of the “loud” control frames to be heard and decoded by all of the potentially contending stations. And because the control frames carry duration information for the virtual carrier sense mechanism, their reception suppresses transmissions by potentially-contending stations that cannot sense the “quiet” Data Frames.

Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject.

This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and / or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and / or Lp(a). Certain diseases, disorders or conditions related to apo(a) and / or Lp(a) include inflammatory, cardiovascular and / or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with said substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of said electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy.

The invention discloses a compound terramycin injection and a preparation method thereof. The compound terramycin injection comprises, by weight, 20 parts of terramycin, 2 parts of flunixin meglumine, 30-40 parts of propylene glycol, 10-15 parts of dimethyl formamide, 3 parts of polyvinylpyrrolidone, 6-7 parts of magnesium oxide, 0.5 parts of an anti-oxidant, 6.1-6.5 parts of ethanolamine and 28 parts of injection water. The compound terramycin injection can be used for treating therapy-sensitive infectious diseases caused by gram-positive bacteria and gram-negative bacteria, rickettsia and mycoplasma and has good treatment effects. The compound terramycin injection has good stability, does not discolor after being heated or stored for a long time, does not product precipitates, solves the problem that under the acid or alkaline conditions, the existing terramycin injection discolors or precipitates after being heated or stored for a long time so that titer is reduced, and can slowly release drug active components in the human body so that long-acting effects are obtained.

Polypeptides are provided that are capable of significantly inhibiting andor neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.

An organic herbicide is disclosed and comprises oxidized natural oils such as clove oil, and cinnamon oil. A natural surfactant is disclosed comprising 30-50% by weight casein, 50-70% by weight whole egg powder and 0-5% by weight Konjac glucomannan.

This document relates to materials and methods for modulating ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and / or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.

The invention pertains to penile implants that facilitate tissue expansion while not substantially inhibiting normal anatomical movement. The implants may be made of different materials or made in different configurations such that such that a measured property at a first location on said implant is different than said same measured property at a second location on said implant.

The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.

The invention relates to a suspending agent for flight control and a preparation method of the suspending agent. The suspending agent contains prothioconazole, trifloxystrobin, a solubilizer, an anti-drifting agent, an anti-transpiration agent and other components according to a specific ratio, has the characteristics of high flash point, fine particle size and normal particle size distribution; and the suspending agent has the characteristics of good stability at high concentration, evaporation resistance, drifting resistance and good wetting spreadability. With the suspending agent adopted,the problems of drifting, demulsification, flocculation, environmental safety and the like in flight control operation can be effectively solved.